Cephalon, Sagent Ink Deal In Generic Cancer Drug Fight
Cephalon Inc. has reached a licensing and settlement agreement with Sagent Pharmaceuticals Inc. to resolve a patent infringement suit over Sagent's plans to market a generic version of Cephalon's top-selling leukemia...To view the full article, register now.
Already a subscriber? Click here to view full article